sFas、sFasL及细胞因子在类风湿关类疾病中的意义

目的：研究sFas、sFasL及细胞因子及抗单链DNA抗体与类风湿关节炎（rheumatoid arthritis,RA)致病的关系及意义。方法采用ELISA法32名RA患者的血清标本。结果RA患者血清sFas、sFasL,IL－6及IL－8的水平均高于正常对照组,活动期sFasL,IL-6及IL－8的水平显著高于非活动期（P＜0．01）,sFas的水平未见显著差异。在32例RA患者中,有8例sFas和sFasL的水平同时升高,9例抗单链DNA抗体和sFasL同时升高。结论IL－6和IL－8的水平与RA的炎症程度有关。高浓度的sFas和sFasL可抑制Ts细胞对TH铁负向调节。由Fas/FasL启动淋巴细胞凋亡产生的核抗原,可致机体产生抗单链DNA抗体。检测sFas,sFasL,IL-6及IL－8有助于对RA匠诊断,并可为RA的免疫生物治疗提供依据。     

肾移植受者血清sFas和sFasL变化及在早期急性排异反应预测中的应用

背景：细胞凋亡在移植免疫和移植物功能丧失发生过程中起十分重要的作用,其中Fas/FasL系统被认为是细胞凋亡参与肾移植的急性排异反应过程的主要途径之一。 目的：分析肾移植受者术后血清sFas和sFasL水平变化及其在预测早期急性排异反应中的应用价值。 方法：肾移植受者80例分为肾功能稳定组(49例)、急性排斥反应组(23例)和环孢素A中毒组(8例)。另选择性别、年龄与肾移植受者相匹配的健康体检者50例为对照组。肾移植受者术后均常规使用环孢素A+硫唑嘌呤+泼尼松三联免疫抑制治疗。发生急性排斥反应时给予每日甲基强的松龙6~8 mg/kg冲击治疗,3 d为1个疗程。采用ELISA法检测患者手术前后的血清sFas和sFasL水平。 结果与结论：肾移植组患者手术前的血清sFas和sFasL水平均明显高于对照组(P  < 0.05)。急性排斥反应组血清sFas、sFasL水平高于相同时间段肾功能稳定组(P < 0.05)。环孢素A中毒的肾移植患者术后各时间点血清sFas、sFasL水平变化与肾功能稳定组基本相同,差异无显著性意义。提示动态监测血清sFas、sFasL水平可能对早期诊断及鉴别诊断肾移植急性排斥反应具有重要参考价值。     

CHF患者血清TNF-α、可溶性Fas和sFasL联检的临床意义

目的:探讨慢性心力衰竭(CHF)患者治疗前后血清TNF-α、sFas和sFasL水平的变化及意义.方法:应用放免法对36例CHF患者进行了治疗前后血清TNF-α、sFas和sFasL的检测,并与35例正常健康人作比较.结果:在CHF治疗前,患者血清TNF-α、sFas和sFasL水平非常显著地高于正常人组(P<0.01...     

不稳定型心绞痛病人血清sFas、sFasL及sIL-2R水平的临床价值

目的　探讨血清sFas、sFasL和sIL 2R水平与不稳定型心绞痛 (Unstableanginapectoris,UAP)之间的关系。方法　应用酶联免疫吸附双抗体夹心 (ELISA)法 ,测定了 32例UAP病人 (UAP组 )和 2 0例对照组受试者血清sFas、sFasL和sIL 2R水平。结果　UAP组病人血清sFas和sIL 2R水平均明显高于对照组 (P <0 .0 1) ,而 2组sFasL水平无显著性差别 (P >0 .0 5 )。UAP组病人sFas水平与sIL 2R水平存在显著正相关 (r=0 .4 4 7,P <0 .0 5 )。结论　高水平的血清sFas、sIL 2R与UAP有关。高水平的血清sFas可能通过维持自身免疫炎性反应而导致UAP的发生发展     

IL-17在类风湿关节炎患者外周血表达的临床意义

目的：探讨IL-17在类风湿关节炎（ RA）发病中的作用及意义。方法：采用逆转录-聚合酶链反应（ RT-PCR）法检测66例RA患者（活动期34例、缓解期32例）和44例健康对照组外周血单个核细胞（ PBMC）中IL-17 mRNA 的表达水平,采用酶联免疫吸附试验（ ELISA）检测各组血清中IL-17的浓度,用免疫比浊法检测各组血清RF的浓度,分析血清IL-17与RF的相关性。结果：RA患者PBMC中IL-17 mRNA的表达显著高于健康对照组（ P＜0.05）,但活动期与缓解期无明显差异（ P＞0.05）;RA活动期患者血清IL-17水平显著高于RA缓解期患者和健康对照组（ P＜0.05）;且RA患者血清IL-17水平与RF呈正相关。结论：IL-17和RF在RA的发病和病理过程中起重要作用,IL-17可能与RA活动性有关。     

泌乳素促进类风湿关节炎患者外周血单个核细胞分泌白细胞介素-6

目的:探讨类风湿关节炎(RA)患者血清泌乳素(PRL)水平与疾病活动程度的关系,以及PRL促进外周血单个核细胞(PBMCs)分泌白细胞介素-6(IL-6)的机制。方法:收集我院2015年3月至9月40例初治RA患者临床及实验室资料。采用化学发光免疫分析法(CLIA)检测血清PRL水平,ELISA检测IL-6水平,RT-q PCR检测泌乳素受体(PRLR)mRNA的表达,Western blot法检测MAPK通路相关蛋白p-p38的蛋白水平。结果:RA患者血清PRL水平明显升高(P0.01),活动期RA患者PRL水平明显高于非活动期RA患者(P0.01)。PRL水平与DAS28评分、ESR和CRP呈正相关(P0.01)。RA患者PBMCs中PRLR水平明显升高(P0.01)。PRL可诱导PBMCs分泌IL-6,siRNA沉默PRLR或采用MAPK通路抑制剂可抑制IL-6的产生。结论:RA患者血清PRL升高与DAS28评分、ESR和CRP呈正相关,PRL可作为预测RA严重程度的指标。PRL通过与PRLR相互作用,激活p38 MAPK通路,从而促进IL-6分泌。     

类风湿关节炎患者血清可溶性髓样细胞触发受体-1、白介素-17水平分析

目的检测类风湿关节炎血清可溶性髓样细胞触发受体1(soluble triggering receptors expressed on myeloid cells-1,sTREM-1)与白介素-17(interleukin-17,IL-17)的血清水平,探讨两者在类风湿关节炎(rheumatoid arthritis,RA)中的变化,分析两者在发病过程中可能作用及临床应用前景。方法应用双抗体夹心酶联免疫吸附试验(ELISA)检测114例RA患者(稳定期组46例、活动期组68例),39例其他风湿免疫系统疾病患者(非RA组)及32例正常对照者血清中可溶性髓样细胞触发受体1(sTREM-1)与白介素-17(IL-17)的水平,同时检测类风湿因子(RHF)、C反应蛋白(CRP)、抗环瓜氨酸肽抗体(anti-CCP)及血沉(ESR)。结果RA组sTREM-1、IL-17较正常对照组高(P=0.03,0.02),且sTREM-1在活动期RA明显高于稳定期RA(P=0.02);RA组血清中sTREM-1与IL-17(r=0.97,P=0.001)、CRP(r=0.255,P=0.006)及ESR(r=0.442,P=0.001)变化呈正相关;未发现sTREM-1、IL-17血清水平变化与病程相关(P=0.64,0.50);两项血清学指标在RA组及非RA组间无统计学意义(P=0.39,0.09)。结论 RA患者sTREM-1水平与反应疾病活动的指标如CRP、ESR水平之间具有良好的相关性;sTREM-1参与RA的发病及疾病活动过程,有可能成为类风湿性关节炎活动性新指标;血清sTREM-1与IL-17水平变化呈正相关,两者在RA发病及病情活动中可能起协同作用。     

联检胃癌患者血清CA19-9、可溶性Fas、sFasL的临床意义

目的：通过联检胃癌患者手术前后血清CA19—9和sFas、sFasL水平变化,探讨其在胃癌早期诊断及复发判断的临床意义。方法：采用电化学发光免疫和ELLSA检测40例胃癌患者手术前后血清CA19—9和sFas、sFasL的含量,并与40例健康体检者进行比较。结果：①胃癌患者手术前后血清CA19—9和sFas、sFasL水平比较有显著差异（P〈0．05）。②胃癌手术前血清CA19—9和sFas、sFasL水平与对照组比较有显著差异（P〈0．05）。③手术成功后CA125和sFasL水平与对照组比较无显著差异（P〉0．05）。结论：①sFas、sFasL的高表达与胃癌的发生、发展密切相关;②sFas、sFasL尤其是sFasL可作为胃癌早期诊断新的血清学诊断标志物,与CA19—9联检,对胃癌患者的疗效观察和复发判断有重要的指导意义。     

环磷酰胺冲击疗法对狼疮性肾炎血清IL—6的影响

目的探讨白介素-6(IL-6)在狼疮性肾炎(LN)发病中的作用及大剂量环磷酰胺静脉给药(IV-CTX)对IL-6产生的影响.方法应用ELISA双抗体夹心法对IV-CTX治疗前后LN患者血清IL-6水平进行检测.结果活动期LN血清IL-6水平显著高于非活动期及健康人(P＜0.001),血清IL-6水平与血沉呈显著正相关(n=22,r=0.570,P＜0.01);抗ds-DNA抗体阳性且血清IgG＞16g/L的LN患者有更高的血清IL-6水平(P＜0.05);活动期LN治疗4w后血清IL-6水平显著下降(P＜0.001).结论LN的B细胞过度活化和自身抗体产生可能与IL-6分泌过量有关.IV-CTX可能通过抑制IL-6的产生而减轻免疫损伤,血清IL-6检测有助于监视狼疮活动和免疫抑制剂疗效.     

严重烧伤患者血清IL-18、sFas和sFasL水平的变化规律及其相关性研究

目的 :探讨严重烧伤患者血清IL 18、sFas和sFasL水平间的变化及其与病情的关系。方法 :选择烧伤总面积(TBSA)≥ 30 %的严重烧伤患者 30例 ,其中死亡 3例 ;正常对照组 4 5例。采用ELISA法对不同时相点 (伤后 1、3、5、7、14、2 1、2 8和 35天 )患者血中IL 18、sFas和sFasL水平进行检测。结果 :与正常对照组比较 ,患者血清IL 18、sFas和sFasL水平均呈显著性上升 (P <0 0 1～ 0 0 5 ) ,并分别持续至伤后 2 8,2 1和 2 1天 ;感染组患者血清IL 18、sFas和sFasL水平均显著地高于非感染组 (P <0 0 1～ 0 0 5 ) ;死亡组患者血清IL 18水平下降 ,而sFasL水平则升高。患者血清IL 18和sFasL水平与烧伤面积相关 ;患者血清IL 18、sFas和sFasL之间也呈显著正相关 (P <0 0 1)。结论 :患者血清IL 18、sFas和sFasL水平与烧伤严重程度及伤后感染密切相关 ,在烧伤后免疫功能及凋亡调控中可能起一定作用。     

Serum levels of soluble Fas ligand in patients with silicosis

Certain patients with silicosis have been reported to exhibit immunological abnormalities such as the appearance of antinuclear antibodies and the occurrence of autoimmune diseases. Fas ligand (FasL) is a type II membrane protein which induces apoptosis by binding to its membrane receptor, Fas. FasL is converted to a soluble form by a metalloproteinase-like enzyme. We have already found serum soluble Fas (sFas) levels in silicosis patients as well as in patients with systemic lupus erythematosus (SLE) to be significantly higher than those in healthy volunteers. To examine further the role of the Fas/FasL system in silica-induced immunological abnormalities, we investigated serum soluble FasL (sFasL) levels in silicosis patients with no clinical symptoms of autoimmune diseases, using ELISA for sFasL. Although the serum sFasL levels in patients with SLE were significantly higher than those in healthy volunteers and showed a slight positive correlation with serum sFas levels, those in silicosis patients exhibited no significant difference from those in healthy volunteers, and there was no correlation with serum sFas levels. However, sFasL levels were elevated in silicosis patients with slight dyspnoea or normal PCO2 among various clinical parameters of silicosis. It may be speculated that the immunological disturbances presented by the abnormalities of apoptosis-related molecules in silicosis patients do not occur with a similar degree of respiratory involvement. Further studies are required to clarify which kinds of factors are involved in silicosis patients who exhibit immunological abnormalities.     

Expression of soluble Fas and soluble FasL in human nucleus pulposus cells

The study aimed for addressing the expression of soluble Fas (sFas) and soluble Fas Ligand (sFasL) in human nucleus pulposus (NP) and its attendant relationship with disc degeneration. Human NP samples were collected from patients with disc degeneration and cadavers as degenerate and normal groups, respectively. Subsequently, NP cells were cultured in monolayer. ELISA was performed to identify the expression levels of sFas and sFasL in the supernatant of NP cell cultures in vitro. Quantitative real-time PCR was used to detect the expression of sFas and sFasL in human NP cells in mRNA solution. The study comprised 12 degenerate and 8 normal cadaveric NP samples. The concentration value of sFas in the supernatant was significantly higher from degenerate NP than that from normal NP at each time point. In contrast, sFasL was significantly lower at each time point. Moreover, the expression of sFas and sFasL reached the peak at various early stages of cell cultures and decreased thereafter. Furthermore, the mRNA level of Fas in degenerate NP cells was significantly higher than that in normal cells; whereas FasL showed an opposite pattern. The study is the first addressing the expression of sFas and sFasL in human NP cell cultures. Moreover, the expression of sFas and sFasL varies with culture time in vitro with different levels in degenerate and normal settings. These findings indicate that sFas and sFasL might play a role in intervertebral disc degeneration.     

Prognostic significance of soluble fas and soluble fas ligand in serum of patients with complete hydatidiform moles

Citation Soni S, Rath G, Deval R, Salhan S, Mishra AKumar, Saxena S. Prognostic significance of soluble Fas and soluble Fas ligand in serum of patients with complete hydatidiform moles. Am J Reprod Immunol 2011; 66: 230–236 Problem Despite of advances in diagnosis and staging, the prognosis of hydatidiform mole (HM) remains intricate. HM possesses the substantial risk of developing persistent trophoblastic disease (PTD), which is considerably high for complete hydatidiform moles (CHMs). Significance of serum soluble Fas (sFas) and soluble FasL (sFasL) has been observed in various malignancies; however, there is no report till date on HM. Method of study The serum levels of sFas and sFasL were measured using enzyme‐linked immunosorbent assay in 62 patients with CHMs and 64 healthy controls. The protein concentrations were also correlated with clinicopathological parameters, β‐hCG level, and clinical outcome. Results The serum sFas and sFasL levels in patients with CHM were significantly higher than those in control group (mean ± SD: 703.497 ± 491.759 versus 348.141 ± 175.24; P < 0.004 and 31.17 ± 18.758 versus 18.802 ± 6.775; P < 0.0001, respectively). Patients who progressed to PTD demonstrated higher sFas and sFasL concentrations than those who regressed spontaneously (794.211 ± 415.892 versus 446.69 ± 161.382; P < 0.046 and 37.55 ± 20.337 versus 22.763 ± 6.52; P < 0.011, respectively). Furthermore, significant associations were observed among sFas, sFasL, and β‐hCG levels (P < 0.0001 for all associations). Conclusion Production of sFas and sFasL may play a crucial role in progression of CHM and may serve both as prognostic tool and therapeutic target in improving the clinical outcome.     

Soluble Fas and soluble Fas L levels in patients with acute pancreatitis

The FasL-Fas system is an apoptosis induction system and plays an important role in homeostasis and biophylaxis. The present study was conducted to investigate soluble Fas (sFas), soluble Fas ligand (sFasL), and tumor necrosis factor alpha (TNF-alpha) in patients with acute pancreatitis. As acute pancreatitis became severe, the levels of sFas in the serum increased significantly, while those of sFasL decreased significantly. A significant inverse correlation was observed between the serum levels of sFas and those of sFasL. Also, a significant positive correlation was observed between the levels of TNF-alpha and sFas. A greater increase in serum sFas and decrease in serum sFasL levels was observed in patients with complicating multiple organ dysfunction syndrome (MODS) than in those without it. The results of the study suggest that the pathological aggravation of acute pancreatitis could be related to changes in the Fas-FasL system.     

Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus

Earlier studies of both chronic hepatitis B and C virus (HBV and HCV) patients have shown a strong correlation between the soluble membrane Fas (sFas) and Fas protein expression on hepatocytes. The serum concentrations of sFas and soluble Fas ligand (sFasL) was examined in both healthy and HBV-infected Vietnamese patients to determine their relationship with the outcome of HBV infection. Patients with chronic rather than acute HBV had significantly higher amounts of sFas and sFasL, whilst the highest concentrations of both molecules were detected in those with malignant forms of HBV infection. sFas and sFasL concentrations tended to increase with a profile that paralleled the progression from asymptomatic to acute through chronic to malignant states, most markedly in the case of sFas. The sFas:sFasL ratio highlighted the relative predominance of sFas in those with acute and chronic HBV compared with asymptomatic or severe forms. In patients with hepatocellular carcinoma (HCC) a significant correlation was also observed between sFasL and alpha-feto protein (AFP) levels. The results indicate that sFas and to a lesser extent sFasL levels are to some degree associated with clinical progression in HBV infection.     

Significance of Fas and Fas ligand in tuberculous lymphadenitis

The Fas/Fas-ligand (FasL) system plays an important role in regulation of apoptosis and the immune response, and is exploited by mycobacteria to evade the immune response. This study was performed to investigate the distribution and levels of FasL and Fas in lymph node granulomas and sera of tuberculous lymphadenitis patients by immunohistochemistry and enzyme-linked immunosorbent assay. The validity of soluble Fas (sFas) or soluble FasL (sFasL) as a diagnostic tool was also examined. Levels of sFasL in serum were elevated among patients. The numbers of FasL stained cells in lymph node granulomas were higher than Fas. Children had significantly higher levels of sFasL as compared to adults. The human immunodeficiency virus (HIV)-tuberculosis (TB)-coinfected patients displayed no differences in the levels of sFasL or sFas compared with HIV-negative patients. The healthy controls from a high endemic tuberculosis country (having latent TB) had significantly higher levels of sFasL than from a country with no TB transmission. The sensitivity and specificity of the FasL and Fas test were low when compared with the culture results as the gold standard. However, by using histology as the gold standard, the sensitivity and specificity of the FasL test were increased to 66.7% and 100%, respectively, but for the Fas test remained low. In conclusion, sFasL and sFas cannot be used as diagnostic tests for tuberculous lymphadenitis. However, its utility in detecting latent TB and childhood tuberculous lymphadenitis remains to be evaluated. FasL seems to play a role in immune modulation and pathogenesis of TB. Modulators of Fas/FasL-mediated apoptosis may therefore be clinically useful.     

Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF

BACKGROUND: There are limited data about the levels of soluble apoptotic factors and their modulation with therapeutic regimens in IVF cycles. The aim of the current study was to determine follicular fluid, and serum levels of soluble Fas (sFas) and soluble Fas ligand (sFasL) in PCOS patients undergoing IVF/ICSI cycles; also to investigate the effects of metformin on these factors and on apoptosis of luteinized granulosa cells. METHODS: We investigated the serum and follicular fluid levels of sFas and sFasL in patients with PCOS (n = 28) and compared them with those of the patients with infertility due to male factor (n = 12) undergoing IVF cycles. Effects of metformin therapy on these parameters and apoptosis of luteinized granulosa cells were also investigated among the patients with PCOS. RESULTS: Serum levels of sFas were significantly lower in the PCOS group compared to those in women with infertility due to male factor. Metformin therapy in PCOS patients preceding IVF cycles increased serum levels of sFas and decreased follicular fluid levels of sFasL compared to those on placebo. Follicular fluid from PCOS patients demonstrated luteinized granulosa cell DNA fragmentation in agarose gel, whereas a similar pattern was not observed among PCOS patients undergoing metformin therapy. CONCLUSION: Decreased serum levels of sFas and luteinized granulosa cell DNA fragmentation is observed in patients with PCOS undergoing IVF cycles. Metformin therapy preceding IVF demonstrates an antiapoptotic effect with increased serum levels of sFas, decreased follicular fluid levels of sFasL and prevention of luteinized granulosa cell DNA fragmentation.     

Alteration of Fas and Fas ligand expression during human visceral leishmaniasis

Several studies in murine systems have suggested a role of apoptosis in the pathogenesis of leishmaniasis. However, the role of apoptosis in visceral leishmaniasis in man has not been explored. In this study, we show that patients with visceral leishmaniasis demonstrate significant dysregulation of Fas and Fas ligand. Levels of soluble Fas (sFas) and soluble Fas ligand (sFasL) were elevated in plasma of patients with active visceral leishmaniasis (VL) and individuals co-infected with VL-HIV-1 compared to healthy controls. The levels of sFas and sFasL were normalized 6 months after successful treatment. In VL patients, the expression of membrane bound Fas, and to a lower extent FasL, were up-regulated on Leishmania donovani-infected spleen cells, the site of parasite multiplication. Expression of Fas and FasL on peripheral blood mononuclear cells was within normal range, probably reflecting that the blood is not a normal site of L. donovani infection. Furthermore, this is suggested by the finding that in vitro infection of macrophages with L. donovani up-regulated Fas expression on the surface of infected cells and enhanced the levels of sFasL in supernatants from infected cultures. How this dysregulation may affect the pathogenesis of human visceral leishmaniasis is discussed.     

Increased serum soluble Fas ligand in hyperthyroid Graves' disease

The interaction of Fas with its ligand (FasL) regulates a number of physiological and pathophysiological process of cell death or apoptosis. Recent studies suggest that Fas and Fas ligand (FasL) interactions among thyrocytes from patients with Hashimoto disease which is caused by thyroid autoimmunity may contribute to clinical hypothyroidism. The role of Fas-FasL interaction in the pathophysiology of Graves' disease has not well been determined. The serum levels of soluble Fas (sFas) and FasL (sFasL) were measured in 48 Japanese patients with Graves' disease (U; untreated hyperthyroidism, T; hyperthyroidism under treatment, E; euthyroidism under treatment and R; remission), destructive thyroiditis (D), subacute thyroiditis (S) and 40 normal controls using commercially available ELISA kits. The levels of sFas (mean +/- SD, ng/ml) were 0.93 +/- 0.30 in normal controls (n = 32), 2.41 +/- 1.28 in U (n = 19), 2.44 +/- 0.79 in T (n = 16), 2.37 +/- 0.55 in E (n = 12), and 2.30 +/- 0.11 in R (n = 6), 2.42 +/- 0.37 in D (n = 3) and 2.68 +/- 0.17 in S (n = 3). There were no significant differences of sFas levels among any groups. While, the mean levels of sFasL (ng/ml) of normal controls were 0.058 +/- 0.02 (n = 40), and those of patients with hyperthyroid Graves' disease (U; 0.34 +/- 0.09 and T; 0.26 +/- 0.05), were significantly higher than those in normal controls (p < 0.005) and with subacute thyroiditis (0.097 +/- 0.001, vs U; p < 0.01, vs T; p < 0.05) but not different from those in E, R and D (E; 0.34 +/- 0.09, R; 0.25 +/- 0.07 and D; 0.31 +/- 0.11, respectively). There was a significant correlation between serum thyrotropin receptor antibody (TRAb) and free thyroxine levels (p < 0.01) while there were no correlation between sFas and sFasL levels and TRAb or free thyroxine levels. The results indicate that the Fas-FasL system contributes to the pathophysiology of hyperthyroid Graves' disease although serum sFas and sFasL levels do not appear to be useful indicators in evaluating disease activity.